TY  - JOUR
AU  - Mezquita-Raya, Pedro
AU  - Darbà, Josep
AU  - Ascanio, Meritxell
AU  - Ramírez de Arellano, Antonio
PY  - 2017
DO  - 10.1080/14737167.2017.1345628
UR  - http://hdl.handle.net/10668/11343
T2  - Expert review of pharmacoeconomics & outcomes research
AB  - The objective of this study was to assess the cost-effectiveness of insulin degludec versus insulin glargine, from the Spanish NHS in three groups of patients. A short-term cost utility model was developed to estimate effectiveness results in terms of...
LA  - en
KW  - Diabetes type 1
KW  - ICER
KW  - costs
KW  - diabetes type 2
KW  - effectiveness
KW  - hypoglycaemic episodes
KW  - insulin degludec
KW  - insulin glargine
KW  - Cost-Benefit Analysis
KW  - Diabetes Mellitus, Type 1
KW  - Diabetes Mellitus, Type 2
KW  - Drug Costs
KW  - Humans
KW  - Hypoglycemia
KW  - Hypoglycemic Agents
KW  - Insulin Glargine
KW  - Insulin, Long-Acting
KW  - Models, Economic
KW  - Quality of Life
KW  - Quality-Adjusted Life Years
KW  - Spain
KW  - Time Factors
TI  - Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective.
TY  - research article
VL  - 17
ER  -